Table 3 Subgroup analysis of sputum culture conversion time among DR-TB patients
Method | Pooled median time (IQR), d | Heterogeneity evaluation | |||
|---|---|---|---|---|---|
T2 | I2 | Q | |||
QE | 68.57 (61.01, 76.12) d | 663.34 | 99.32% | 5149.79 (P < 0.0001) | |
Category | Subgroup | No. of studie | Sample size | Median time (IQR),d | P-val |
World Health Organization regions | Africa | 15 | 2780 | 69.42d (56.35, 82.49) | < 0.0001 (I2 = 98.71%) |
Europe | 5 | 1627 | 53.15d (40.39, 65.91) | < 0.0001 (I2 = 92.37%) | |
Southeast Asia | 8 | 7701 | 85.94d (63.00, 108.88) | < 0.0001 (I2 = 99.73%) | |
America | 2 | 881 | 59.64d (56.92, 62.37) | 0.73 (I2 = 0%) | |
Eastern Mediterranean | 2 | 787 | 59.22d (54.56, 63.88) | 0.86 (I2 = 0%) | |
Western Pacific Ocean | 11 | 1715 | 63.27d (46.78, 79.76) | < 0.0001 (I2 = 97.39%) | |
National development level | developed country | 6 | 2771 | 57.63d (40.48, 74.78) | < 0.0001 (I2 = 96.12%) |
developing country | 37 | 12,716 | 69.97d (61.35, 78.59) | < 0.0001 (I2 = 99.41%) | |
Treatment regimen | without bedaquiline | 26 | 8895 | 73.36d (65.68, 81.04) | < 0.0001 (I2 = 97.76%) |
Contain bedaquiline | 9 | 1003 | 49.39d (34.95, 63.83) | < 0.0001 (I2 = 96.67%) | |